Isomorphic Labs secures $5 billion in second major round
Isomorphic Labs, Alphabet’s artificial intelligence drug-discovery company, has raised $5 billion in a financing round led jointly by Greenoaks and Sequoia Capital. Andreessen Horowitz participated as a new investor, while Alphabet and all existing backers also took part. The company raised $2.1 billion in May 2026, making this its second billion-dollar round within six months.
The funding is intended to advance IsoDDE, or the Isomorphic Drug Design Engine, and move the company’s drug candidates closer to clinical trials. Isomorphic Labs, founded in 2021, says IsoDDE goes beyond AlphaFold 3 by seeking to improve predictions of how drugs bind and where they dock.
The company collaborates with Novartis, Eli Lilly and Johnson & Johnson, but has not yet produced an approved medicine. It is led by Demis Hassabis, who became Alphabet’s Chief Scientist after leaving day-to-day leadership of Google DeepMind in August 2026. Hassabis shared the 2024 Nobel Prize in Chemistry with John Jumper for work on AlphaFold. DeepMind’s original AlphaFold team was disbanded in July; some researchers joined Isomorphic Labs or moved to other projects, while nearly a quarter left DeepMind.
Written by Sakhanda Wire AI from reporting by The Decoder. Facts, quotes and full context are in the original article below.